10-Q: BillionToOne Reports Strong Q1 2026 Growth

BillionToOne, Inc. announces significant revenue and profit increase in Q1 2026, driven by strong test volume and ASP growth in prenatal and oncology diagnostics.

Summary

• BillionToOne, Inc. reported a substantial increase in revenue for the first quarter ended March 31, 2026, reaching $108.4 million, an 84% increase compared to $59.0 million in the same period of 2025.
• Net income for the quarter was $18.0 million, a significant turnaround from a net loss of $4.0 million in Q1 2025.
• The company's gross profit more than doubled to $79.1 million, with gross margin improving to 73% from 64% year-over-year.
• Total test volume (accessioned) increased by 44% to approximately 189,000 tests in Q1 2026, compared to 137,000 in Q1 2025.
• The average selling price (ASP) across all products increased by 28%.
• The company drew down the third tranche of its Oberland Capital debt, receiving $30.0 million.
• Cash and cash equivalents increased to $537.5 million as of March 31, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, improved profitability, and a healthy cash position, although material weaknesses in internal controls warrant attention.

Positives

• Revenue surged by 84% to $108.4 million in Q1 2026, driven by strong test volume and ASP growth.
• The company achieved net income of $18.0 million, a significant improvement from a net loss in the prior year.
• Gross profit more than doubled to $79.1 million, with gross margin expanding to 73% from 64%.
• Test volume increased by 44%, indicating strong market adoption and demand for its diagnostic solutions.
• Overall ASP increased by 28%, reflecting successful payor contracting and value proposition.
• The company successfully drew down the third tranche of its Oberland Capital debt, adding $30.0 million in financing.
• Cash and cash equivalents grew to $537.5 million, providing a strong liquidity position.

Negatives

• Despite improved profitability, the company still has an accumulated deficit of $256.8 million as of March 31, 2026.
• The company reported material weaknesses in its internal control over financial reporting, which remain unremediated.
• Selling, general, and administrative expenses increased by 56% to $46.6 million, driven by headcount expansion.
• The change in fair value of the term loan resulted in a loss of $4.3 million for the quarter.

Risks

• The company faces risks related to the adoption and commercial success of its prenatal and oncology products.
• Payor coverage, contracting, and reimbursement remain critical as over 90% of revenue is derived from third-party payors.
• The company is subject to regulatory risks and potential violations of healthcare laws.
• Material weaknesses in internal control over financial reporting could lead to misstatements in financial reporting.
• The company's future capital requirements may necessitate additional financing, which may not be available on favorable terms.
• Competition in the molecular diagnostics market is intense, and competitors may initiate legal proceedings.

Future Outlook

The company expects revenue to increase over time due to expanded sales efforts, new product introductions, and increased payor contracts. Investments in R&D are expected to continue, potentially leading to increased R&D costs in absolute dollars but a moderate decline as a percentage of revenue. SG&A expenses are also expected to increase due to sales and marketing expansion and public company compliance costs. The company anticipates that its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months.

Management Comments

• "Our business momentum is evidenced by our rapidly scaling commercial success and improving operational efficiency."
• "We believe that the combined effects of ASP increases, cost of goods sold (COGS) decreases, and improved operational efficiency have been the main drivers of our ability to generate net income in recent periods."
• "We have invested in building a high-performing, specialized team dedicated to all aspects of reimbursement, including claims management, appeals, and payor relations."
• "We actively seek ways to continuously reduce our costs-per-test and improve our gross profit margin, long-term profitability, and return on investment."
• "We believe that our continued focus in optimization, automation, and AI for higher operational efficiencies will drive further productivity gains."

Industry Context

StockSavvy.ai notes that BillionToOne's strong Q1 2026 performance, particularly the significant revenue growth and improved gross margins, aligns with the broader trend of increasing demand for advanced molecular diagnostics in both prenatal and oncology care. The company's focus on AI and automation in its operations and reimbursement processes is a key differentiator in a competitive landscape.

Comparison to Industry Standards

• BillionToOne's gross margin of 73% in Q1 2026 is notably strong compared to many companies in the diagnostics sector, which often operate with lower margins due to high R&D and regulatory costs.
• The company's revenue growth of 84% year-over-year significantly outpaces the average growth rates seen in the broader healthcare diagnostics market.
• The increase in test volume, particularly in prenatal diagnostics where they claim to test approximately 1 in 11 babies in the US, suggests a strong market penetration that may exceed that of some competitors in specific niches.
• While specific competitor data is not provided in the filing, the company's stated strategy of leveraging guideline changes for its UNITY Fetal Antigen CTA to contract with more insurance companies is a common and effective approach in the industry to increase ASP and market access.

Legal Proceedings

• The company is involved in legal claims, regulatory investigations, inquiries, proceedings, and other legal matters arising in the normal course of business.
• From time to time, the company receives requests for documents and information related to its products from governmental agencies or third parties.

Related Party Transactions

• No material related party transactions were disclosed for the three months ended March 31, 2026 and 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong financial performance and increased net income, though material weaknesses in internal controls may pose a risk.
• Employees: Continued investment in R&D and sales/marketing headcount suggests growth and potential for new opportunities. Stock-based compensation remains a significant expense.
• Customers (Physicians/Healthcare Systems): Access to advanced diagnostic tools that can improve patient care and outcomes.
• Payors (Insurance Companies, Medicare/Medicaid): Increased volume of tests may lead to higher reimbursement payouts, but the company's focus on contracting and ASP increases aims to manage this.
• Creditors: The company's strong cash position and improved profitability reduce financial risk.

Next Steps

• Continue to expand sales efforts and introduce new products.
• Focus on increasing payor contracts and reimbursement rates.
• Invest in research and development for new molecular diagnostic assays and enhancements.
• Continue to optimize operations, automate workflows, and integrate AI for efficiency gains.
• Occupy the new laboratory facility in Austin, Texas in 2027 and open for commercial samples in 2028.
• Develop a tissue-free, pan-cancer MRD test, expected to be commercially available in Q4 2026.

Key Dates

Recommendation

The Q1 2026 results demonstrate exceptional revenue growth, a significant turnaround to profitability, and expanding gross margins, driven by strong test volume and ASP increases. The company's strategic investments in technology, AI, and operational efficiency are yielding substantial results. While material weaknesses in internal controls require ongoing attention, the overall financial and operational performance indicates a company on a strong growth trajectory with significant market potential in precision diagnostics.

Keywords

BillionToOne, Form 10-Q, Quarterly Report, Prenatal Diagnostics, Oncology Diagnostics, Molecular Diagnostics, NIPT, Liquid Biopsy, Revenue Growth, Gross Margin, Net Income, Financial Results, SEC Filing